SCHEMBL696830

SCHEMBL696830

[O]NC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539827 0.62
SCHEMBL129372 0.62
SCHEMBL2108630 0.59
SCHEMBL524052 0.59
SCHEMBL145655 0.59
SCHEMBL8960980 0.59
SCHEMBL13401283 0.59
SCHEMBL994280 0.59
SCHEMBL993345 0.59
SCHEMBL2819234 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023056589-A1 MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER SERVIER PHARMACEUTICALS LLC (US) 2023-04-13 WO claimed
EP-2975021-B1 PROCESS FOR THE PREPARATION OF IOPAMIDOL BRACCO IMAGING SPA (IT) 2017-07-26 EP claimed
EP-2975021-A1 PROCESS FOR THE PREPARATION OF IOPAMIDOL Bracco Imaging SPA (IT) 2016-01-20 EP claimed
WO-2008152388-A1 SILICON-CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF BONE LOSS OR RESTORATION OF BONE MASS, OR AUGMENTATION OF BONE MASS OPAL DRUG DISCOVERY LIMITED (GB) 2008-12-18 WO claimed
US-7442702-B2 Treatment of bone disorders; carboxy derivatives PFIZER INC. (US) 2008-10-28 US claimed
EP-1021410-B1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER (US) 2006-12-27 EP claimed
CN-1859903-A Use of EP2 selective receptor agonists in medical treatment PFIZER PROD INC (US) 2006-11-08 CN claimed
US-7034183-B2 Process for the preparation of iopamidol and the new intermediated therein BRACCO IMAGING S.P.A. (IT) 2006-04-25 US claimed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US claimed
EP-1601351-A1 USE OF EP2 SELECTIVE RECEPTOR AGONISTS IN MEDICAL TREATMENT Pfizer Products Inc. (US) 2005-12-07 EP claimed
WO-1998027976-A1 PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS PFIZER INC. (US) 1998-07-02 WO claimed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO claimed
EP-0191858-B1 POLY(ARYLCYCLOBUTENES)MONOMERSAND A METHOD OF POLYMERISING THEREOF THE DOW CHEMICAL COMPANY (US) 1990-11-14 EP claimed
EP-0195785-A4 polymeric composition derived from poly(arylcyclobutenes) and a process for preparing said polymeric composition. DOW CHEMICAL CO (US) 1987-09-02 EP claimed
EP-0191858-A4 POLY(ARYLCYCLOBUTENES)MONOMERSand a method of polymerising thereof. DOW CHEMICAL CO (US) 1987-01-10 EP claimed
EP-0195785-A1 polymeric composition derived from poly(arylcyclobutenes) and a process for preparing said polymeric composition. DOW CHEMICAL CO (US) 1986-10-01 EP claimed
EP-0191858-A1 POLY(ARYLCYCLOBUTENES)MONOMERSand a method of polymerising thereof. DOW CHEMICAL CO (US) 1986-08-27 EP claimed
WO-1986001809-A1 POLYMERS DERIVED FROM POLY(ARYLCYCLOBUTENES) THE DOW CHEMICAL COMPANY (US) 1986-03-27 WO claimed
WO-1986001503-A1 POLY(ARYLCYCLOBUTENES)MONOMERS THE DOW CHEMICAL COMPANY (US) 1986-03-13 WO claimed
US-4540763-A Polymers derived from poly(arylcyclobutenes) THE DOW CHEMICAL COMPANY (US) 1985-09-10 US claimed